View ValuationZhongchao 将来の成長Future 基準チェック /06現在、 Zhongchaoの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Consumer Services 収益成長12.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Apr 06Full year 2025 earnings released: US$1.85 loss per share (vs US$0.99 loss in FY 2024)Full year 2025 results: US$1.85 loss per share (further deteriorated from US$0.99 loss in FY 2024). Revenue: US$11.4m (down 28% from FY 2024). Net loss: US$6.31m (loss widened US$5.67m from FY 2024).New Risk • Mar 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 126% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 52% per year over the past 5 years. Shareholders have been substantially diluted in the past year (126% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$14.3m market cap).分析記事 • Feb 13Zhongchao Inc. (NASDAQ:ZCMD) Looks Inexpensive After Falling 60% But Perhaps Not Attractive EnoughZhongchao Inc. ( NASDAQ:ZCMD ) shareholders that were waiting for something to happen have been dealt a blow with a 60...New Risk • Feb 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$7.76m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 52% per year over the past 5 years. Market cap is less than US$10m (US$7.76m market cap). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding).New Risk • Dec 31New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (US$18.9m market cap).分析記事 • Dec 30Some Zhongchao Inc. (NASDAQ:ZCMD) Shareholders Look For Exit As Shares Take 32% PoundingTo the annoyance of some shareholders, Zhongchao Inc. ( NASDAQ:ZCMD ) shares are down a considerable 32% in the last...Reported Earnings • Oct 05First half 2025 earnings released: US$0.038 loss per share (vs US$0.034 profit in 1H 2024)First half 2025 results: US$0.038 loss per share (down from US$0.034 profit in 1H 2024). Revenue: US$5.60m (down 33% from 1H 2024). Net loss: US$965.3k (down US$1.06m from profit in 1H 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.分析記事 • Sep 20Zhongchao Inc. (NASDAQ:ZCMD) Stock Rockets 28% As Investors Are Less Pessimistic Than ExpectedZhongchao Inc. ( NASDAQ:ZCMD ) shareholders are no doubt pleased to see that the share price has bounced 28% in the...New Risk • Sep 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 64% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$24.0m market cap).分析記事 • Jun 22What Zhongchao Inc.'s (NASDAQ:ZCMD) 28% Share Price Gain Is Not Telling YouZhongchao Inc. ( NASDAQ:ZCMD ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...分析記事 • Jun 19Here's Why We're Watching Zhongchao's (NASDAQ:ZCMD) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...New Risk • Jun 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 64% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$33.6m market cap).Reported Earnings • Apr 27Full year 2024 earnings released: US$0.12 loss per share (vs US$4.35 loss in FY 2023)Full year 2024 results: US$0.12 loss per share (improved from US$4.35 loss in FY 2023). Revenue: US$15.9m (down 18% from FY 2023). Net loss: US$643.2k (loss narrowed 94% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.分析記事 • Feb 28Zhongchao Inc.'s (NASDAQ:ZCMD) Popularity With Investors Is Under Threat From OverpricingIt's not a stretch to say that Zhongchao Inc.'s ( NASDAQ:ZCMD ) price-to-sales (or "P/S") ratio of 1.8x right now seems...分析記事 • Nov 15Zhongchao Inc.'s (NASDAQ:ZCMD) 32% Dip In Price Shows Sentiment Is Matching RevenuesZhongchao Inc. ( NASDAQ:ZCMD ) shares have had a horrible month, losing 32% after a relatively good period beforehand...お知らせ • Nov 07Zhongchao Inc., Annual General Meeting, Dec 18, 2024Zhongchao Inc., Annual General Meeting, Dec 18, 2024, at 09:00 China Standard Time. Location: nanxi creative center, suite 218, 841 yanan middle road, jingan district, shanghai, ChinaNew Risk • Oct 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 116% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 68% per year over the past 5 years. Shareholders have been substantially diluted in the past year (116% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$14.3m market cap).お知らせ • Oct 02Zhongchao Inc. has filed a Follow-on Equity Offering in the amount of $0.9282 million.Zhongchao Inc. has filed a Follow-on Equity Offering in the amount of $0.9282 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 3,094,000 Price\Range: $0.3 Discount Per Security: $0 Transaction Features: Registered Direct Offering分析記事 • Oct 01Zhongchao Inc. (NASDAQ:ZCMD) Surges 76% Yet Its Low P/S Is No Reason For ExcitementDespite an already strong run, Zhongchao Inc. ( NASDAQ:ZCMD ) shares have been powering on, with a gain of 76% in the...New Risk • Oct 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 27% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 68% per year over the past 5 years. Market cap is less than US$10m (US$3.39m market cap).分析記事 • Aug 10Zhongchao Inc.'s (NASDAQ:ZCMD) Shares Bounce 32% But Its Business Still Trails The IndustryZhongchao Inc. ( NASDAQ:ZCMD ) shareholders would be excited to see that the share price has had a great month, posting...Reported Earnings • May 02Full year 2023 earnings released: US$4.35 loss per share (vs US$1.13 loss in FY 2022)Full year 2023 results: US$4.35 loss per share (further deteriorated from US$1.13 loss in FY 2022). Revenue: US$19.4m (up 37% from FY 2022). Net loss: US$11.3m (loss widened 286% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.分析記事 • Apr 27Zhongchao Inc.'s (NASDAQ:ZCMD) Shares Bounce 32% But Its Business Still Trails The IndustryThose holding Zhongchao Inc. ( NASDAQ:ZCMD ) shares would be relieved that the share price has rebounded 32% in the...分析記事 • Mar 07Benign Growth For Zhongchao Inc. (NASDAQ:ZCMD) Underpins Stock's 30% PlummetTo the annoyance of some shareholders, Zhongchao Inc. ( NASDAQ:ZCMD ) shares are down a considerable 30% in the last...分析記事 • Dec 28Little Excitement Around Zhongchao Inc.'s (NASDAQ:ZCMD) Revenues As Shares Take 50% PoundingUnfortunately for some shareholders, the Zhongchao Inc. ( NASDAQ:ZCMD ) share price has dived 50% in the last thirty...Reported Earnings • Dec 27First half 2023 earnings released: US$0.18 loss per share (vs US$0.004 profit in 1H 2022)First half 2023 results: US$0.18 loss per share (down from US$0.004 profit in 1H 2022). Revenue: US$10.4m (up 42% from 1H 2022). Net loss: US$4.72m (down US$4.82m from profit in 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance.New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 37% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (4.3% increase in shares outstanding). Market cap is less than US$100m (US$20.8m market cap).New Risk • Nov 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 37% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (4.3% increase in shares outstanding). Market cap is less than US$100m (US$22.4m market cap).お知らせ • Sep 26Zhongchao Inc. Introduces Pro-Based Disease Management Model for Lung Cancer PatientsZhongchao Inc. announced the introduction of its Patient-Reported Outcome (PRO)-based symptom management model. This model is geared toward aiding the recovery of lung cancer patients and enhancing their life quality. Many lung cancer patients are grappling with a multitude of symptoms throughout their treatment process, including but not limited to fatigue, reduced appetite, nausea, and approximately 34 other symptoms. These symptoms can lead to emotional turmoil towards patients, manifesting as anxiety or depression, severely impacting patients' life quality and their overall recovery process. The PRO-based symptom management method prioritizes genuine feedbacks from patients about their health conditions, which aids in accurately identifying underlying health concerns and enhancing overall well-being. A study published in the "Journal of Clinical Oncology" in 2022 also highlighted that a PRO-driven model integrating proactive Symptom Monitoring, Alerting, and Response System can significantly reduce post-discharge symptoms and complications in lung cancer patients, accelerate their post-operative recovery and receive high satisfaction from patients. Zhongchao's existing patient management services already features a comprehensive range of offerings for lung cancer patients. The expert-led seminars could guide patients and offer direct engagement through mobile applications to answer their queries virtually. The seminars ensure patients fully understand their treatment journey and can enhance their adherence to treatment protocols. Zhongchao also provides a suite of resources through mobile applications, including, among the others, educational contents, disease follow-up visits, lifestyle advice, drug aids information and other support services. To facilitate efficient and one-on-one patient communications, Zhongchao has established robust follow-up channels through various platforms such as phones, WeChat, and text messages, staffed by dedicated disease management specialists. Unlike the existing patient management services, which focus primarily on medical aspects such as Duration of Therapy, the newly introduced PRO-based management model shifts the focus towards patients' own experiences and feelings about their health, bringing a fresh perspective into patient care. By actively collecting and analyzing patient feedback on physical symptoms, emotional states, self-perceptions and other PRO data, the Company is able to continually refine its management methods, aiming to enhance the living standards and well-being of lung cancer patients.Reported Earnings • May 14Full year 2022 earnings released: US$0.11 loss per share (vs US$0.01 profit in FY 2021)Full year 2022 results: US$0.11 loss per share (down from US$0.01 profit in FY 2021). Revenue: US$14.2m (down 13% from FY 2021). Net loss: US$2.94m (down US$3.18m from profit in FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.お知らせ • Feb 09Zhongchao Inc. Announces the Application of ChatGPT to Elevate Patient Management Service Capabilities and ExperienceZhongchao Inc. announced the application of ChatGPT (Chat Generative Pre-trained Transformer) for content creation and patient interactions to enhance the capabilities in delivering quality experience of patient management services. ChatGPT is a language model developed by OpenAI that learns and produces conversational content through natural language processing powered by artificial intelligence technology to interact with users in chat and continuously learn to improve the user experience. The Sunshine Health Forums and Zhongxin, both operated by the PRC operating entities that Zhongchao consolidates the financial statements with through certain contractual agreements, provide medical knowledge education and treatment process management services with patients through a comprehensive array of resources, including media matrix, anti-cancer encyclopedia, online consultation, and medication management. These platforms offer patients with instant answers and clarifications for complex and professional issues and questions encountered during self-diagnosis, diagnostic and treatment process, serving as a valuable reference for patients' consultation, treatment, and health maintenance. Given the wide variety of human diseases and the huge amount of medical information, patient management requires efficient production of massive medical content and prompt patient interactions. In a further effort to enhance patient experience, Zhongchao will apply ChatGPT on the existing platforms of Wechat Public Account and Mini-Program on WeChat to improve the efficiency of producing graphics, videos, and other contents, promptly respond and interact with patients, and manage patient emotions and experiences. Zhongchao places a strong emphasis on delivering a superior patient experience. In addition, patients will be alerted that contents provided by ChatGPT will be solely for reference and convenience to users and shall not be relied on for diagnostic or treatment purposes. To address patients' demand for personalized services, the Company may plan to harness ChatGPT's power of advanced thinking and computing capabilities to develop customized disease management models and intelligent tools that cater to the specific needs and conditions of each patient, ensuring patients receiving individualized and tailored services regardless of their varying disease types, stages, health conditions, and mental states.Reported Earnings • Dec 18First half 2022 earnings released: EPS: US$0.004 (vs US$0.04 in 1H 2021)First half 2022 results: EPS: US$0.004 (down from US$0.04 in 1H 2021). Revenue: US$7.30m (down 15% from 1H 2021). Net income: US$93.5k (down 91% from 1H 2021). Profit margin: 1.3% (down from 12% in 1H 2021). The decrease in margin was driven by lower revenue.お知らせ • Dec 06Zhongchao Inc. Establishes SID Liver Cancer Comprehensive-Disciplinary Physician Education PlatformZhongchao Inc. announced that after three years of preparation, the Company's MDMOOC platform has established a "Surgical-Interventional-Drug" ("SID") platform for liver cancer comprehensive-disciplinary physician education ("SID Platform"), providing physicians with knowledge and techniques in comprehensive-disciplinary comprehensive management of patients with liver cancer. The SID Platform created by Zhongchao targets physicians from different levels and covers comprehensive disciplines of liver cancer treatment: hepatobiliary surgery, interventional and medical oncology. Led by the Key Opinion Leaders ("KOL") of liver cancer disciplines, the SID Platform designs and provides clinical diagnosis and treatment education courses in liver cancer and provides a technical platform for clinicians to share experiences and discuss clinical challenges. As of now, the courses on the SID Platform were taken approximately 290,000 times by liver cancer physicians. Zhongchao believes that its SID Platform provides a platform for liver cancer physicians, especially for junior and intermediate physicians to present themselves, learn knowledge and techniques, and communicate with peers, which promotes new liver cancer treatment concepts such as conversion therapy, comprehensive patient management and standardized interventional treatments. Zhongchao expects its SID Platform to serve as a new model of promotion and education platform, contribute to the lifelong learning and professional development of liver cancer physicians, and eventually benefit liver cancer patients.Board Change • Dec 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Kevin Dean Vassily was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Sep 02Zhongchao Inc. Announces Its New Strategy Extension Focusing on the Oncology and Other Major Disease ManagementZhongchao Inc. announced its newly added business section of oncology and other major disease management which is a part of its development strategy to extend its business model from "Medical-Pharmaceutical" to "Medical-Pharmaceutical-Patient." Utilizing its accumulated experiences in medical education and innovation, and extensive resources with medical professionals and pharmaceuticals, Zhongchao is well positioned to become a platform that provides patients with major disease management services. The Company has implemented several strategic initiatives to transform to the new "Medical-Pharmaceutical-Patient" model. In 2021, Zhongchao launched patient management business focusing on the professional field of tumor and rare disease through its subsidiary Shanghai Zhongxin Medical Technology Co. Ltd. ("Zhongxin"), which was the important first step of the transform. The strategy to extend business model was driven by the increased demands of "patient-oriented" healthcare in China. Management have been closely observing and monitoring such service model that is to provide medical services and disease management tailored to individual patient and allow patient to actively initiate and participate in health management and disease treatment since its appearance in 2021. It is worth to mention that the Company's self-developed patient management system successfully improved Duration of Therapy ("DOT") by 40.4% for liver cancer patients, contributing to the maximum efficiency of drugs, successful treatment and longer patient survival terms, as compared to patients without using the management system, based on the data collected by the Company during a period from November 2017 to September 2021. As a result, the Company plans to continue the development of patient management services through Zhongxin. As of now, Zhongxin provides comprehensive disease education and management services for tumor patients receiving treatment. Through services such as drug aids, disease follow-up visits, medication management, and cancer education promotion, Zhongxin helps tumor patients reduce the economic burden of treatment and promote the completion the treatment process, resulting in the best treatment effect and improvement the quality of life for the patients. As of now, more than hundreds of thousand oncology Patients have used either the application developed by Zhongxin or WeChat network service platform to connect patients with Zhongxin's hotline center and service commissioner system and received disease management support.お知らせ • Jun 15Zhongchao Inc., Annual General Meeting, Jul 28, 2022Zhongchao Inc., Annual General Meeting, Jul 28, 2022, at 21:00 China Standard Time. Location: Nanxi Creative Center, Suite 218, 841 Yan’an Middle Road Jing’An District, Shanghai, People’s Republic of China Jing'an China Agenda: To elect each of the five directors named in this notice to shareholders (the “Proxy Statement”) to hold office until the next annual meeting of shareholders and until his/her respective successor is elected and duly qualified; and To approve the appointment of Marcum Bernstein & Pinchuk LLP, as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2022.お知らせ • May 03Zhongchao Inc. announced delayed 20-F filingOn 05/02/2022, Zhongchao Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC.分析記事 • Apr 14Some Investors May Be Worried About Zhongchao's (NASDAQ:ZCMD) Returns On CapitalIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...Valuation Update With 7 Day Price Move • Mar 12Investor sentiment deteriorated over the past weekAfter last week's 39% share price decline to US$1.05, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 19x in the Consumer Services industry in the US. Total loss to shareholders of 44% over the past year.分析記事 • Oct 15Investors Could Be Concerned With Zhongchao's (NASDAQ:ZCMD) Returns On CapitalThere are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Seeking Alpha • Sep 21Zhongchao Inc.: Ask Why?Zhongchao Inc. is a China-based healthcare information, education, training & services provider. Floated in February 2020, the 3 million share-offering raised circa $12M. Since then, the stock has tanked losing about 60% of its value. The Chinese government’s crackdown on capital raising abroad provides headwinds for China-based equities. Before any investment decision, ask why.お知らせ • Aug 26Zhongchao Inc.'s Subsidiary Shanghai Zhongxin Medical Technology Co., Ltd Expands Patient Management Business to Ovarian Cancer MarketZhongchao Inc. announced its subsidiary Shanghai Zhongxin Medical Technology Co. Ltd. ("Zhongxin") provides patient follow-up management services for ovarian cancer patients from Zeyoulexiang Patient Assistance Project (the "Project"), helping ovarian cancer patients improve treatment outcomes and eventually increase survival rate. The Project, managed by Bethune Charitable Foundation, provides assistance to female patients in mainland China who meet the standards to take Niraparib, an anti-cancer medication. Through the all-in-one patient management system ("All-in-One System") developed by the Company, patients can record, track and view various indications of their bodies and disease during the medication and receive early warnings of potential disease progression to manage adverse reactions and psychological problems during medication and improve their adherence to treatment and treatment safety. In addition, the digital follow-up function embedded in the All-in-One System allows patient management specialists and physicians to provide one-on-one medication guidance and lifestyle advice for patients to ensure correct drugs usage and response to adverse reactions, improving the treatment experience.Seeking Alpha • Jun 29Zhongchao: Cheap Growth And Value Healthcare Education StockZhongchao is a provider of healthcare education/training/services in China. Lost 56.6% of its value since IPO in March 2020. Price drop mainly caused by struggles to communicate its brand and its value to investors. Operates in a growing and large market. Excellent earnings/revenue valuation and growth rates. The price drop made it cheap too.お知らせ • May 29Zhongchao Inc. Launches New Line of BusinessZhongchao Inc. announced the launch of the patient management service focusing on the professional field of tumor and rare disease operated through its subsidiary Shanghai Zhongxin Medical Technology Co. Ltd. Zhongchao has been closely following up on the new study and research of tumor and rare disease both in China and worldwide. Based on the statistics provided by World Health Organization'sInternational Agency for Research on Cancer, there were approximately 19.29 million new cancer cases and 10 million cancer deaths globally in 2020. China had approximately 4.57 million new cancer cases in 2020, accounting for approximately 23.7% of the total cancer cases around the world. China'sNational Health Commission indicated that there are approximately 20 million patients with rare disease in China. Medical treatment markets for both cancer and rare diseases have been expanding along with the increasing number of patients. The Company has realized that, in addition to drug development and more advanced medical treatment options, patients' active engagements in the treatment is also critical to lead to better overall treatment outcomes such as higher chemotherapy completion rate, lower rehospitalization risk and longer survival time. Many multinational pharmaceutical companies have also realized such significance by conducting strategic investments in not only drug developments but also patient management projects. With our MDMOOC online platform which provides information, education, and training services for healthcare professionals and Sunshine Health Forums which provides healthcare knowledge for the public, the Company could provide technical supports for Zhongxin's patient management services to assist patients with tumor or rare disease. Zhongxin plans to build a comprehensive patient management system with integrated data insights into existing clinical workflows.分析記事 • May 11A Piece Of The Puzzle Missing From Zhongchao Inc.'s (NASDAQ:ZCMD) Share PriceWith a price-to-earnings (or "P/E") ratio of 9.7x Zhongchao Inc. ( NASDAQ:ZCMD ) may be sending very bullish signals at...Reported Earnings • May 03Full year 2020 earnings released: EPS US$0.18 (vs US$0.19 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: US$18.0m (up 21% from FY 2019). Net income: US$4.46m (up 10% from FY 2019). Profit margin: 25% (down from 27% in FY 2019). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Mar 18Investor sentiment improved over the past weekAfter last week's 54% share price gain to US$2.66, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 23x in the Consumer Services industry in the US. Total returns to shareholders of 21% over the past year.Valuation Update With 7 Day Price Move • Feb 27Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$1.91, the stock is trading at a trailing P/E ratio of 11.5x, down from the previous P/E ratio of 13.7x. This compares to an average P/E of 25x in the Consumer Services industry in the US. Total return to shareholders over the past year is a loss of 51%.分析記事 • Feb 23How Much Did Zhongchao's(NASDAQ:ZCMD) Shareholders Earn From Share Price Movements Over The Last Year?While not a mind-blowing move, it is good to see that the Zhongchao Inc. ( NASDAQ:ZCMD ) share price has gained 24% in...Is New 90 Day High Low • Feb 13New 90-day high: US$2.22The company is up 10.0% from its price of US$2.02 on 13 November 2020. The American market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is up 21% over the same period.Valuation Update With 7 Day Price Move • Feb 11Investor sentiment improved over the past weekAfter last week's 15% share price gain to US$2.14, the stock is trading at a trailing P/E ratio of 12.9x, up from the previous P/E ratio of 11.2x. This compares to an average P/E of 24x in the Consumer Services industry in the US.分析記事 • Jan 08We're Not So Sure You Should Rely on Zhongchao's (NASDAQ:ZCMD) Statutory EarningsStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said that...Is New 90 Day High Low • Jan 07New 90-day low: US$1.68The company is down 8.0% from its price of US$1.82 on 08 October 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is down 7.0% over the same period.Valuation Update With 7 Day Price Move • Dec 25Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$1.76, the stock is trading at a trailing P/E ratio of 10.6x, down from the previous P/E ratio of 12.7x. This compares to an average P/E of 27x in the Consumer Services industry in the US.Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improved over the past weekAfter last week's 20% share price gain to US$2.11, the stock is trading at a trailing P/E ratio of 12.7x, up from the previous P/E ratio of 10.6x. This compares to an average P/E of 28x in the Consumer Services industry in the US.Valuation Update With 7 Day Price Move • Nov 19Market pulls back on stock over the past weekAfter last week's 18% share price decline to US$1.77, the stock is trading at a trailing P/E ratio of 10.7x, down from the previous P/E ratio of 13x. This compares to an average P/E of 28x in the Consumer Services industry in the US.Valuation Update With 7 Day Price Move • Nov 13Market bids up stock over the past weekAfter last week's 16% share price gain to US$2.15, the stock is trading at a trailing P/E ratio of 13x, up from the previous P/E ratio of 11.2x. This compares to an average P/E of 28x in the Consumer Services industry in the US.Is New 90 Day High Low • Oct 03New 90-day low: US$1.70The company is down 21% from its price of US$2.16 on 02 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is up 12% over the same period.Reported Earnings • Sep 22First half earnings releasedOver the last 12 months the company has reported total profits of US$3.77m, down 10% from the prior year. Total revenue was US$16.4m over the last 12 months, up 12% from the prior year. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Zhongchao は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NasdaqCM:ZCMD - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202511-611N/A9/30/202512-400N/A6/30/202513-2-10N/A3/31/202514-1-3-1N/A12/31/202416-1-5-1N/A9/30/202417-4-21N/A6/30/202417-703N/A3/31/202418-901N/A12/31/202319-11-10N/A9/30/202318-10-2-1N/A6/30/202317-8-4-2N/A3/31/202316-5-3-1N/A12/31/202214-3-3-1N/A9/30/202215-2-10N/A6/30/202215-100N/A3/31/202216012N/A12/31/202116013N/A9/30/202117213N/A6/30/202118403N/A3/31/2021184-11N/A12/31/2020184-2-1N/A9/30/2020174-10N/A6/30/202016400N/A3/31/202016401N/A12/31/201915401N/A9/30/2019154N/A0N/A6/30/2019154N/A-2N/A3/31/2019144N/A0N/A12/31/2018133N/A1N/A12/31/2017102N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ZCMDの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ZCMDの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ZCMDの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ZCMDの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ZCMDの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ZCMDの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YConsumer-services 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/31 07:13終値2026/05/29 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Zhongchao Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Apr 06Full year 2025 earnings released: US$1.85 loss per share (vs US$0.99 loss in FY 2024)Full year 2025 results: US$1.85 loss per share (further deteriorated from US$0.99 loss in FY 2024). Revenue: US$11.4m (down 28% from FY 2024). Net loss: US$6.31m (loss widened US$5.67m from FY 2024).
New Risk • Mar 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 126% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 52% per year over the past 5 years. Shareholders have been substantially diluted in the past year (126% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$14.3m market cap).
分析記事 • Feb 13Zhongchao Inc. (NASDAQ:ZCMD) Looks Inexpensive After Falling 60% But Perhaps Not Attractive EnoughZhongchao Inc. ( NASDAQ:ZCMD ) shareholders that were waiting for something to happen have been dealt a blow with a 60...
New Risk • Feb 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$7.76m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 52% per year over the past 5 years. Market cap is less than US$10m (US$7.76m market cap). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding).
New Risk • Dec 31New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (US$18.9m market cap).
分析記事 • Dec 30Some Zhongchao Inc. (NASDAQ:ZCMD) Shareholders Look For Exit As Shares Take 32% PoundingTo the annoyance of some shareholders, Zhongchao Inc. ( NASDAQ:ZCMD ) shares are down a considerable 32% in the last...
Reported Earnings • Oct 05First half 2025 earnings released: US$0.038 loss per share (vs US$0.034 profit in 1H 2024)First half 2025 results: US$0.038 loss per share (down from US$0.034 profit in 1H 2024). Revenue: US$5.60m (down 33% from 1H 2024). Net loss: US$965.3k (down US$1.06m from profit in 1H 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
分析記事 • Sep 20Zhongchao Inc. (NASDAQ:ZCMD) Stock Rockets 28% As Investors Are Less Pessimistic Than ExpectedZhongchao Inc. ( NASDAQ:ZCMD ) shareholders are no doubt pleased to see that the share price has bounced 28% in the...
New Risk • Sep 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 64% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$24.0m market cap).
分析記事 • Jun 22What Zhongchao Inc.'s (NASDAQ:ZCMD) 28% Share Price Gain Is Not Telling YouZhongchao Inc. ( NASDAQ:ZCMD ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...
分析記事 • Jun 19Here's Why We're Watching Zhongchao's (NASDAQ:ZCMD) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
New Risk • Jun 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 64% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$33.6m market cap).
Reported Earnings • Apr 27Full year 2024 earnings released: US$0.12 loss per share (vs US$4.35 loss in FY 2023)Full year 2024 results: US$0.12 loss per share (improved from US$4.35 loss in FY 2023). Revenue: US$15.9m (down 18% from FY 2023). Net loss: US$643.2k (loss narrowed 94% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.
分析記事 • Feb 28Zhongchao Inc.'s (NASDAQ:ZCMD) Popularity With Investors Is Under Threat From OverpricingIt's not a stretch to say that Zhongchao Inc.'s ( NASDAQ:ZCMD ) price-to-sales (or "P/S") ratio of 1.8x right now seems...
分析記事 • Nov 15Zhongchao Inc.'s (NASDAQ:ZCMD) 32% Dip In Price Shows Sentiment Is Matching RevenuesZhongchao Inc. ( NASDAQ:ZCMD ) shares have had a horrible month, losing 32% after a relatively good period beforehand...
お知らせ • Nov 07Zhongchao Inc., Annual General Meeting, Dec 18, 2024Zhongchao Inc., Annual General Meeting, Dec 18, 2024, at 09:00 China Standard Time. Location: nanxi creative center, suite 218, 841 yanan middle road, jingan district, shanghai, China
New Risk • Oct 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 116% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 68% per year over the past 5 years. Shareholders have been substantially diluted in the past year (116% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$14.3m market cap).
お知らせ • Oct 02Zhongchao Inc. has filed a Follow-on Equity Offering in the amount of $0.9282 million.Zhongchao Inc. has filed a Follow-on Equity Offering in the amount of $0.9282 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 3,094,000 Price\Range: $0.3 Discount Per Security: $0 Transaction Features: Registered Direct Offering
分析記事 • Oct 01Zhongchao Inc. (NASDAQ:ZCMD) Surges 76% Yet Its Low P/S Is No Reason For ExcitementDespite an already strong run, Zhongchao Inc. ( NASDAQ:ZCMD ) shares have been powering on, with a gain of 76% in the...
New Risk • Oct 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 27% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 68% per year over the past 5 years. Market cap is less than US$10m (US$3.39m market cap).
分析記事 • Aug 10Zhongchao Inc.'s (NASDAQ:ZCMD) Shares Bounce 32% But Its Business Still Trails The IndustryZhongchao Inc. ( NASDAQ:ZCMD ) shareholders would be excited to see that the share price has had a great month, posting...
Reported Earnings • May 02Full year 2023 earnings released: US$4.35 loss per share (vs US$1.13 loss in FY 2022)Full year 2023 results: US$4.35 loss per share (further deteriorated from US$1.13 loss in FY 2022). Revenue: US$19.4m (up 37% from FY 2022). Net loss: US$11.3m (loss widened 286% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.
分析記事 • Apr 27Zhongchao Inc.'s (NASDAQ:ZCMD) Shares Bounce 32% But Its Business Still Trails The IndustryThose holding Zhongchao Inc. ( NASDAQ:ZCMD ) shares would be relieved that the share price has rebounded 32% in the...
分析記事 • Mar 07Benign Growth For Zhongchao Inc. (NASDAQ:ZCMD) Underpins Stock's 30% PlummetTo the annoyance of some shareholders, Zhongchao Inc. ( NASDAQ:ZCMD ) shares are down a considerable 30% in the last...
分析記事 • Dec 28Little Excitement Around Zhongchao Inc.'s (NASDAQ:ZCMD) Revenues As Shares Take 50% PoundingUnfortunately for some shareholders, the Zhongchao Inc. ( NASDAQ:ZCMD ) share price has dived 50% in the last thirty...
Reported Earnings • Dec 27First half 2023 earnings released: US$0.18 loss per share (vs US$0.004 profit in 1H 2022)First half 2023 results: US$0.18 loss per share (down from US$0.004 profit in 1H 2022). Revenue: US$10.4m (up 42% from 1H 2022). Net loss: US$4.72m (down US$4.82m from profit in 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance.
New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 37% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (4.3% increase in shares outstanding). Market cap is less than US$100m (US$20.8m market cap).
New Risk • Nov 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 37% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (4.3% increase in shares outstanding). Market cap is less than US$100m (US$22.4m market cap).
お知らせ • Sep 26Zhongchao Inc. Introduces Pro-Based Disease Management Model for Lung Cancer PatientsZhongchao Inc. announced the introduction of its Patient-Reported Outcome (PRO)-based symptom management model. This model is geared toward aiding the recovery of lung cancer patients and enhancing their life quality. Many lung cancer patients are grappling with a multitude of symptoms throughout their treatment process, including but not limited to fatigue, reduced appetite, nausea, and approximately 34 other symptoms. These symptoms can lead to emotional turmoil towards patients, manifesting as anxiety or depression, severely impacting patients' life quality and their overall recovery process. The PRO-based symptom management method prioritizes genuine feedbacks from patients about their health conditions, which aids in accurately identifying underlying health concerns and enhancing overall well-being. A study published in the "Journal of Clinical Oncology" in 2022 also highlighted that a PRO-driven model integrating proactive Symptom Monitoring, Alerting, and Response System can significantly reduce post-discharge symptoms and complications in lung cancer patients, accelerate their post-operative recovery and receive high satisfaction from patients. Zhongchao's existing patient management services already features a comprehensive range of offerings for lung cancer patients. The expert-led seminars could guide patients and offer direct engagement through mobile applications to answer their queries virtually. The seminars ensure patients fully understand their treatment journey and can enhance their adherence to treatment protocols. Zhongchao also provides a suite of resources through mobile applications, including, among the others, educational contents, disease follow-up visits, lifestyle advice, drug aids information and other support services. To facilitate efficient and one-on-one patient communications, Zhongchao has established robust follow-up channels through various platforms such as phones, WeChat, and text messages, staffed by dedicated disease management specialists. Unlike the existing patient management services, which focus primarily on medical aspects such as Duration of Therapy, the newly introduced PRO-based management model shifts the focus towards patients' own experiences and feelings about their health, bringing a fresh perspective into patient care. By actively collecting and analyzing patient feedback on physical symptoms, emotional states, self-perceptions and other PRO data, the Company is able to continually refine its management methods, aiming to enhance the living standards and well-being of lung cancer patients.
Reported Earnings • May 14Full year 2022 earnings released: US$0.11 loss per share (vs US$0.01 profit in FY 2021)Full year 2022 results: US$0.11 loss per share (down from US$0.01 profit in FY 2021). Revenue: US$14.2m (down 13% from FY 2021). Net loss: US$2.94m (down US$3.18m from profit in FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 09Zhongchao Inc. Announces the Application of ChatGPT to Elevate Patient Management Service Capabilities and ExperienceZhongchao Inc. announced the application of ChatGPT (Chat Generative Pre-trained Transformer) for content creation and patient interactions to enhance the capabilities in delivering quality experience of patient management services. ChatGPT is a language model developed by OpenAI that learns and produces conversational content through natural language processing powered by artificial intelligence technology to interact with users in chat and continuously learn to improve the user experience. The Sunshine Health Forums and Zhongxin, both operated by the PRC operating entities that Zhongchao consolidates the financial statements with through certain contractual agreements, provide medical knowledge education and treatment process management services with patients through a comprehensive array of resources, including media matrix, anti-cancer encyclopedia, online consultation, and medication management. These platforms offer patients with instant answers and clarifications for complex and professional issues and questions encountered during self-diagnosis, diagnostic and treatment process, serving as a valuable reference for patients' consultation, treatment, and health maintenance. Given the wide variety of human diseases and the huge amount of medical information, patient management requires efficient production of massive medical content and prompt patient interactions. In a further effort to enhance patient experience, Zhongchao will apply ChatGPT on the existing platforms of Wechat Public Account and Mini-Program on WeChat to improve the efficiency of producing graphics, videos, and other contents, promptly respond and interact with patients, and manage patient emotions and experiences. Zhongchao places a strong emphasis on delivering a superior patient experience. In addition, patients will be alerted that contents provided by ChatGPT will be solely for reference and convenience to users and shall not be relied on for diagnostic or treatment purposes. To address patients' demand for personalized services, the Company may plan to harness ChatGPT's power of advanced thinking and computing capabilities to develop customized disease management models and intelligent tools that cater to the specific needs and conditions of each patient, ensuring patients receiving individualized and tailored services regardless of their varying disease types, stages, health conditions, and mental states.
Reported Earnings • Dec 18First half 2022 earnings released: EPS: US$0.004 (vs US$0.04 in 1H 2021)First half 2022 results: EPS: US$0.004 (down from US$0.04 in 1H 2021). Revenue: US$7.30m (down 15% from 1H 2021). Net income: US$93.5k (down 91% from 1H 2021). Profit margin: 1.3% (down from 12% in 1H 2021). The decrease in margin was driven by lower revenue.
お知らせ • Dec 06Zhongchao Inc. Establishes SID Liver Cancer Comprehensive-Disciplinary Physician Education PlatformZhongchao Inc. announced that after three years of preparation, the Company's MDMOOC platform has established a "Surgical-Interventional-Drug" ("SID") platform for liver cancer comprehensive-disciplinary physician education ("SID Platform"), providing physicians with knowledge and techniques in comprehensive-disciplinary comprehensive management of patients with liver cancer. The SID Platform created by Zhongchao targets physicians from different levels and covers comprehensive disciplines of liver cancer treatment: hepatobiliary surgery, interventional and medical oncology. Led by the Key Opinion Leaders ("KOL") of liver cancer disciplines, the SID Platform designs and provides clinical diagnosis and treatment education courses in liver cancer and provides a technical platform for clinicians to share experiences and discuss clinical challenges. As of now, the courses on the SID Platform were taken approximately 290,000 times by liver cancer physicians. Zhongchao believes that its SID Platform provides a platform for liver cancer physicians, especially for junior and intermediate physicians to present themselves, learn knowledge and techniques, and communicate with peers, which promotes new liver cancer treatment concepts such as conversion therapy, comprehensive patient management and standardized interventional treatments. Zhongchao expects its SID Platform to serve as a new model of promotion and education platform, contribute to the lifelong learning and professional development of liver cancer physicians, and eventually benefit liver cancer patients.
Board Change • Dec 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Kevin Dean Vassily was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Sep 02Zhongchao Inc. Announces Its New Strategy Extension Focusing on the Oncology and Other Major Disease ManagementZhongchao Inc. announced its newly added business section of oncology and other major disease management which is a part of its development strategy to extend its business model from "Medical-Pharmaceutical" to "Medical-Pharmaceutical-Patient." Utilizing its accumulated experiences in medical education and innovation, and extensive resources with medical professionals and pharmaceuticals, Zhongchao is well positioned to become a platform that provides patients with major disease management services. The Company has implemented several strategic initiatives to transform to the new "Medical-Pharmaceutical-Patient" model. In 2021, Zhongchao launched patient management business focusing on the professional field of tumor and rare disease through its subsidiary Shanghai Zhongxin Medical Technology Co. Ltd. ("Zhongxin"), which was the important first step of the transform. The strategy to extend business model was driven by the increased demands of "patient-oriented" healthcare in China. Management have been closely observing and monitoring such service model that is to provide medical services and disease management tailored to individual patient and allow patient to actively initiate and participate in health management and disease treatment since its appearance in 2021. It is worth to mention that the Company's self-developed patient management system successfully improved Duration of Therapy ("DOT") by 40.4% for liver cancer patients, contributing to the maximum efficiency of drugs, successful treatment and longer patient survival terms, as compared to patients without using the management system, based on the data collected by the Company during a period from November 2017 to September 2021. As a result, the Company plans to continue the development of patient management services through Zhongxin. As of now, Zhongxin provides comprehensive disease education and management services for tumor patients receiving treatment. Through services such as drug aids, disease follow-up visits, medication management, and cancer education promotion, Zhongxin helps tumor patients reduce the economic burden of treatment and promote the completion the treatment process, resulting in the best treatment effect and improvement the quality of life for the patients. As of now, more than hundreds of thousand oncology Patients have used either the application developed by Zhongxin or WeChat network service platform to connect patients with Zhongxin's hotline center and service commissioner system and received disease management support.
お知らせ • Jun 15Zhongchao Inc., Annual General Meeting, Jul 28, 2022Zhongchao Inc., Annual General Meeting, Jul 28, 2022, at 21:00 China Standard Time. Location: Nanxi Creative Center, Suite 218, 841 Yan’an Middle Road Jing’An District, Shanghai, People’s Republic of China Jing'an China Agenda: To elect each of the five directors named in this notice to shareholders (the “Proxy Statement”) to hold office until the next annual meeting of shareholders and until his/her respective successor is elected and duly qualified; and To approve the appointment of Marcum Bernstein & Pinchuk LLP, as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2022.
お知らせ • May 03Zhongchao Inc. announced delayed 20-F filingOn 05/02/2022, Zhongchao Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
分析記事 • Apr 14Some Investors May Be Worried About Zhongchao's (NASDAQ:ZCMD) Returns On CapitalIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...
Valuation Update With 7 Day Price Move • Mar 12Investor sentiment deteriorated over the past weekAfter last week's 39% share price decline to US$1.05, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 19x in the Consumer Services industry in the US. Total loss to shareholders of 44% over the past year.
分析記事 • Oct 15Investors Could Be Concerned With Zhongchao's (NASDAQ:ZCMD) Returns On CapitalThere are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
Seeking Alpha • Sep 21Zhongchao Inc.: Ask Why?Zhongchao Inc. is a China-based healthcare information, education, training & services provider. Floated in February 2020, the 3 million share-offering raised circa $12M. Since then, the stock has tanked losing about 60% of its value. The Chinese government’s crackdown on capital raising abroad provides headwinds for China-based equities. Before any investment decision, ask why.
お知らせ • Aug 26Zhongchao Inc.'s Subsidiary Shanghai Zhongxin Medical Technology Co., Ltd Expands Patient Management Business to Ovarian Cancer MarketZhongchao Inc. announced its subsidiary Shanghai Zhongxin Medical Technology Co. Ltd. ("Zhongxin") provides patient follow-up management services for ovarian cancer patients from Zeyoulexiang Patient Assistance Project (the "Project"), helping ovarian cancer patients improve treatment outcomes and eventually increase survival rate. The Project, managed by Bethune Charitable Foundation, provides assistance to female patients in mainland China who meet the standards to take Niraparib, an anti-cancer medication. Through the all-in-one patient management system ("All-in-One System") developed by the Company, patients can record, track and view various indications of their bodies and disease during the medication and receive early warnings of potential disease progression to manage adverse reactions and psychological problems during medication and improve their adherence to treatment and treatment safety. In addition, the digital follow-up function embedded in the All-in-One System allows patient management specialists and physicians to provide one-on-one medication guidance and lifestyle advice for patients to ensure correct drugs usage and response to adverse reactions, improving the treatment experience.
Seeking Alpha • Jun 29Zhongchao: Cheap Growth And Value Healthcare Education StockZhongchao is a provider of healthcare education/training/services in China. Lost 56.6% of its value since IPO in March 2020. Price drop mainly caused by struggles to communicate its brand and its value to investors. Operates in a growing and large market. Excellent earnings/revenue valuation and growth rates. The price drop made it cheap too.
お知らせ • May 29Zhongchao Inc. Launches New Line of BusinessZhongchao Inc. announced the launch of the patient management service focusing on the professional field of tumor and rare disease operated through its subsidiary Shanghai Zhongxin Medical Technology Co. Ltd. Zhongchao has been closely following up on the new study and research of tumor and rare disease both in China and worldwide. Based on the statistics provided by World Health Organization'sInternational Agency for Research on Cancer, there were approximately 19.29 million new cancer cases and 10 million cancer deaths globally in 2020. China had approximately 4.57 million new cancer cases in 2020, accounting for approximately 23.7% of the total cancer cases around the world. China'sNational Health Commission indicated that there are approximately 20 million patients with rare disease in China. Medical treatment markets for both cancer and rare diseases have been expanding along with the increasing number of patients. The Company has realized that, in addition to drug development and more advanced medical treatment options, patients' active engagements in the treatment is also critical to lead to better overall treatment outcomes such as higher chemotherapy completion rate, lower rehospitalization risk and longer survival time. Many multinational pharmaceutical companies have also realized such significance by conducting strategic investments in not only drug developments but also patient management projects. With our MDMOOC online platform which provides information, education, and training services for healthcare professionals and Sunshine Health Forums which provides healthcare knowledge for the public, the Company could provide technical supports for Zhongxin's patient management services to assist patients with tumor or rare disease. Zhongxin plans to build a comprehensive patient management system with integrated data insights into existing clinical workflows.
分析記事 • May 11A Piece Of The Puzzle Missing From Zhongchao Inc.'s (NASDAQ:ZCMD) Share PriceWith a price-to-earnings (or "P/E") ratio of 9.7x Zhongchao Inc. ( NASDAQ:ZCMD ) may be sending very bullish signals at...
Reported Earnings • May 03Full year 2020 earnings released: EPS US$0.18 (vs US$0.19 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: US$18.0m (up 21% from FY 2019). Net income: US$4.46m (up 10% from FY 2019). Profit margin: 25% (down from 27% in FY 2019). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Mar 18Investor sentiment improved over the past weekAfter last week's 54% share price gain to US$2.66, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 23x in the Consumer Services industry in the US. Total returns to shareholders of 21% over the past year.
Valuation Update With 7 Day Price Move • Feb 27Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$1.91, the stock is trading at a trailing P/E ratio of 11.5x, down from the previous P/E ratio of 13.7x. This compares to an average P/E of 25x in the Consumer Services industry in the US. Total return to shareholders over the past year is a loss of 51%.
分析記事 • Feb 23How Much Did Zhongchao's(NASDAQ:ZCMD) Shareholders Earn From Share Price Movements Over The Last Year?While not a mind-blowing move, it is good to see that the Zhongchao Inc. ( NASDAQ:ZCMD ) share price has gained 24% in...
Is New 90 Day High Low • Feb 13New 90-day high: US$2.22The company is up 10.0% from its price of US$2.02 on 13 November 2020. The American market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is up 21% over the same period.
Valuation Update With 7 Day Price Move • Feb 11Investor sentiment improved over the past weekAfter last week's 15% share price gain to US$2.14, the stock is trading at a trailing P/E ratio of 12.9x, up from the previous P/E ratio of 11.2x. This compares to an average P/E of 24x in the Consumer Services industry in the US.
分析記事 • Jan 08We're Not So Sure You Should Rely on Zhongchao's (NASDAQ:ZCMD) Statutory EarningsStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said that...
Is New 90 Day High Low • Jan 07New 90-day low: US$1.68The company is down 8.0% from its price of US$1.82 on 08 October 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is down 7.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 25Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$1.76, the stock is trading at a trailing P/E ratio of 10.6x, down from the previous P/E ratio of 12.7x. This compares to an average P/E of 27x in the Consumer Services industry in the US.
Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improved over the past weekAfter last week's 20% share price gain to US$2.11, the stock is trading at a trailing P/E ratio of 12.7x, up from the previous P/E ratio of 10.6x. This compares to an average P/E of 28x in the Consumer Services industry in the US.
Valuation Update With 7 Day Price Move • Nov 19Market pulls back on stock over the past weekAfter last week's 18% share price decline to US$1.77, the stock is trading at a trailing P/E ratio of 10.7x, down from the previous P/E ratio of 13x. This compares to an average P/E of 28x in the Consumer Services industry in the US.
Valuation Update With 7 Day Price Move • Nov 13Market bids up stock over the past weekAfter last week's 16% share price gain to US$2.15, the stock is trading at a trailing P/E ratio of 13x, up from the previous P/E ratio of 11.2x. This compares to an average P/E of 28x in the Consumer Services industry in the US.
Is New 90 Day High Low • Oct 03New 90-day low: US$1.70The company is down 21% from its price of US$2.16 on 02 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is up 12% over the same period.
Reported Earnings • Sep 22First half earnings releasedOver the last 12 months the company has reported total profits of US$3.77m, down 10% from the prior year. Total revenue was US$16.4m over the last 12 months, up 12% from the prior year.